Management of Pruritus in CKD Patients on Maintenance Hemodialysis
Start with optimizing dialysis adequacy and correcting metabolic abnormalities, then use emollients for xerosis; for persistent moderate-to-severe pruritus, broadband UVB phototherapy (BB-UVB) is the most effective treatment with the highest strength of evidence (Strength A), followed by gabapentin 100-300 mg post-dialysis three times weekly as an alternative. 1
Stepwise Management Algorithm
First-Line: Foundational Measures (Before Pharmacotherapy)
Before considering specific antipruritic treatments, address these modifiable factors 1:
- Ensure adequate dialysis: Target Kt/V around 1.6; consider high-flux hemodialysis over standard filtration
- Normalize calcium-phosphate balance: Correct hyperphosphatemia and hypercalcemia
- Control parathyroid hormone to accepted KDIGO levels
- Correct anemia with erythropoietin
- Apply simple emollients liberally for xerosis (dry skin), which affects 67.8% of patients and lowers the itch threshold 2
These foundational steps are essential because pruritus is more common in underdialysed patients, and metabolic derangements (elevated corrected calcium, hyperphosphatemia) are independently associated with CKD-associated pruritus 3. Additionally, limiting interdialytic weight gain and ultrafiltration volume may help, as higher UF volume/body weight ratios independently predict pruritus severity 4.
Second-Line: Phototherapy (Highest Quality Evidence)
BB-UVB phototherapy is the most effective treatment for uraemic pruritus with Strength of Recommendation A 1. This represents the strongest evidence grade in the British Association of Dermatologists guidelines.
- Start with 300 mJ/cm² twice weekly
- Increase dose by 10% per session
- Expect significant VAS score reduction (from 8.48 to 4.76 over 8 weeks in recent studies) 2
- No significant side effects observed during treatment
- Narrowband UVB (NB-UVB) is also effective
Third-Line: Gabapentin (Alternative to Phototherapy)
If phototherapy is unavailable or impractical, gabapentin 100-300 mg post-dialysis three times weekly is effective 1:
- Start with 100 mg post-dialysis (note: much lower doses than non-ESRD populations)
- Can increase to 300 mg three times weekly after dialysis
- Expect >50% reduction in VAS scores
- Main side effect: mild drowsiness
- Also improves depression and sleep disturbances associated with pruritus 1
Fourth-Line: Topical Agents
Consider these options 1:
- Capsaicin cream: Depletes substance P in peripheral sensory neurons
- Topical calcipotriol: May provide relief
Critical Pitfalls to Avoid
Do NOT use sedative antihistamines long-term (Strength of Recommendation B) - they may predispose to dementia except in palliative care settings 1. This is one of the few "B" strength recommendations in the guidelines.
Cetirizine is NOT effective in uraemic pruritus (Strength D) 1. Despite being commonly prescribed, it showed no benefit in hemodialysis patients.
Alternative Considerations
If standard treatments fail 1:
- Auricular acupressure or aromatherapy (Strength D)
- Activated charcoal showed significant improvement in RCTs 1
- Ketotifen may be as effective as gabapentin in some studies 1
Definitive Treatment
Renal transplantation is the only definitive cure (Strength D) 1. In desperate cases with refractory pruritus, patients suitable for transplantation might be prioritized 5.
Clinical Context
Pruritus affects 40-67.5% of hemodialysis patients depending on assessment scale used 1, 4, 3, though recent data from Jiangsu Province showed 9.28% prevalence with 27% having severe pruritus 3. The symptom significantly impacts quality of life, with severe cases showing higher rates of sleep disturbance (71.57%), cardiovascular disease (38.48%), and cerebrovascular disease (10.66%) 3. The median patient reports 9 symptoms total, with fatigue affecting at least half 6.
No single topical or systemic treatment strategy is universally effective 1, which is why the algorithmic approach starting with foundational measures and progressing to BB-UVB or gabapentin is critical. The bilateral, symmetrical, non-dermatomal distribution affecting back, limbs, chest, and head helps distinguish CKD-associated pruritus from other causes 7.